N-methyl-D-aspartate increases the excitability of nigrostriatal dopamine terminals.
The terminal excitability of nigrostriatal dopamine cells was measured before and after i.v. administration of N-methyl-D-aspartate (NMDA; 1 or 4 mg/kg), the competitive NMDA antagonist AP-7 (2-amino-7-phosphonoheptanoic acid) (4 mg/kg) or saline. NMDA produced a dose-dependent increase in terminal excitability, in the absence of an effect on the somal membrane, whereas AP-7 and saline were without effect. These data provide convergent in vivo evidence that glutamate can enhance striatal dopamine release via the NMDA receptor.
Overton
P
P
Department of Psychology, University of Reading, Berkshire, U.K.
Clark
D
D
D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives*; D000200:Action Potentials / Q000187:drug effects; D000596:Amino Acids / Q000494:pharmacology; D000818:Animals; D001667:Binding, Competitive; D003342:Corpus Striatum / Q000187:drug effects* / Q000502:physiology; D004298:Dopamine / Q000378:metabolism*; D008297:Male; D016202:N-Methylaspartate / Q000494:pharmacology*; D009412:Nerve Fibers / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains; D013378:Substantia Nigra / Q000187:drug effects / Q000502:physiology
D000596:Amino Acids; D016202:N-Methylaspartate; D015763:2-Amino-5-phosphonovalerate; C031231:2-amino-7-phosphonoheptanoic acid; D004298:Dopamine